Health & bio
Every item from Trenri daily that fell into Health & bio, latest first.
May 2026 Β· 55
BMS signs up-to-$15.2B 13-pipeline megadeal with China's Hengrui
Bristol Myers Squibb signed a global licensing and co-development agreement with Hengrui on May 12 covering 13 early-stage oncology, hematology, and immunology programs. The deal includes a $600M upfront payment and up to $950M in near-term payments, with total potential value reaching $15.2B including milestones and royalties. Hengrui's Hong Kong-listed shares jumped more than 13%.
Roche Alzheimer's blood test pTau217 receives European CE mark
Roche announced on May 12 that its Elecsys plasma pTau217 test, co-developed with Eli Lilly, received the European CE mark. Unlike pTau181, it supports not only ruling out Alzheimer's pathology but also confirming it, reducing the burden of invasive CSF testing and brain imaging. CE-market launch is planned for July 2026.
Eli Lilly overtakes Novo Nordisk in ex-U.S. GLP-1 share
Q1 overseas Mounjaro revenue reached $8.7B, beating consensus and allowing Eli Lilly to overtake Novo Nordisk in non-U.S. GLP-1 market share for the first time. In oral GLP-1s, however, Novo's Wegovy pill launched first in January and appears to be seeing faster early uptake than Lilly's Foundayo, or orforglipron, launched in April.
Trump administration MFN drug-pricing policy reaches voluntary deals with 17 pharma firms
The White House said in May 12 materials that its most-favored-nation drug-pricing policy has secured voluntary agreements with 17 global pharmaceutical companies and would save federal and state Medicaid programs $64.3B over ten years. Industry resistance continues, however, with list prices for 872 branded drugs rising a median 4% so far in 2026.
Rare-disease pipelines advance at AskBio and BridgeBio; telehealth Hims misses
AskBio dosed the first patient in a phase 1/2 gene-therapy trial for late-onset Pompe disease, while BridgeBio filed an FDA new-drug application for encaleret in autosomal dominant hypocalcemia type 1. Meanwhile, as telehealth competition in compounded GLP-1s intensified, Hims & Hers reported quarterly revenue below consensus on May 12 and shares weakened.
MV Hondius: 94 evacuated, WHO reassures
The Dutch cruise ship MV Hondius, carrying Andes hantavirus cases, docked in Canary Islands on May 10, disembarking 94 passengers from 19 countries. Three died, seven confirmed, nine suspected. Human-to-human transmission confirmed in some cases, but WHO Director Tedros said general public risk is low.
VYVGART PDUFA May 10; Intellia CRISPR shows gains
argenx VYVGART (efgartigimod) for seronegative generalized myasthenia hits May 10 PDUFA. Intellia's lonvo-z for hereditary angioedema showed 87% attack-rate cut vs. placebo in phase 3, with 60% remaining attack-free (vs. 11% placebo), signaling the first in vivo CRISPR path to approval.
Foundayo vs. Wegovy: GLP-1 oral duel
Lilly's oral Foundayo (orforglipron) saw 20,000+ patients begin dosing post-launch, 1,000 new scripts per day, 80% new-to-GLP1. Novo's Wegovy pill leads with tens of thousands on board in four months. Novo holds 2026 revenue/profit guidance at -5% to -13%.
β¦ RELATED THESISH5N1 case in Bangladesh child; U.S. vigilant
WHO Q1 2026 report logged 13 zoonotic flu human infections including one Bangladesh child H5N1 death (unreported earlier). U.S. dairy and poultry worker exposures remain sporadic; no sustained human-to-human spread. CDC rates public risk 'low'.
Korean biosimilars' golden decade
Samsung Bioepis' Pyzchiva (Stelara equivalent) cracked U.S. top-3 ustekinumab market in one year. Celltrion's Steqeyma gains via Costco. Global pharma M&A races to bag biosimilar firms ahead of blockbuster patent cliffs.
MV Hondius Hantavirus: 3 Deaths, 6 Confirmed as Ship Reaches Tenerife
WHO confirmed 6 of 8 suspected cases with 3 deaths (2 confirmed Andes variant) as of May 9. Over 100 passengers, including 17 Americans, began disembarkation in the Canary Islands with U.S. and UK deploying evacuation aircraft.
β¦ RELATED THESISViridian Elegrobart Phase 3 REVEAL-2 Achieves 50% PRR in Chronic Thyroid Eye Disease
May 5 Phase 3 REVEAL-2 data showed 50% partial response rate (versus 15% placebo) for four-weekly elegrobart dosing, with eight-weekly achieving 54%, securing Q1 2027 BLA filing pathway.
CMS Launches July 2026 Medicare GLP-1 Obesity Pilot
May 6 CMS announced GLP-1 bridge model (July 2026βDecember 2027) offering discount coverage for Wegovy, Zepbound KwikPen, Foundayo tablets for Medicare enrollees with BMI 27+ (with comorbidities) or BMI 35+.
β¦ RELATED THESISArvinas Veppanu Becomes First PROTAC FDA Approval for ESR1-Mutant Breast Cancer
May 1 FDA approval of Arvinas' vepdegestrant (Veppanu) for ER+/HER2β/ESR1-mutant advanced/metastatic breast cancer marks first commercial PROTAC (heterobifunctional protein degrader) success.
Capricor Deramiocel Phase 3 HOPE-3 Meets Primary in Duchenne Muscular Dystrophy
Phase 3 HOPE-3 met PUL v2.0 primary endpoint, with reduced cardiac LGE progression (p=0.022) and improved LVEF (p=0.017). PDUFA date set for August 22, 2026.
β¦ RELATED THESISLilly Foundayo (orforglipron) Approved as First Non-Peptide GLP-1 Weight-Loss Pill
FDA approved Lilly's Foundayo on 4/1 for chronic weight management. As the first non-peptide GLP-1 receptor agonist oral formulation, it eliminates meal and water restrictions. CNPV priority review determined the action in 50 days.
β¦ RELATED THESISVeppanu (vepdegestrant) Approved for ER+/HER2- Metastatic Breast Cancer
FDA approved Veppanu on 5/1 for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations. This marks the first success of the heterobifunctional protein degradation class.
Novo Nordisk Wegovy Oral Formulation; First GLP-1 Weight-Loss Tablet
FDA approved Novo Nordisk's Wegovy oral tablet as the first GLP-1 medication in pill form for weight loss. Tablet availability reduces patient reluctance versus injection therapy, accelerating market expansion.
β¦ RELATED THESISNuvation Bio Files IBTROZI sNDA for ROS1-Positive NSCLC
Nuvation Bio submitted a supplemental NDA on 5/6 for IBTROZI (taletrectinib) in advanced ROS1-positive NSCLC. Target action date: January 4, 2027.
FDA Authorizes Four Glas E-Cigarette Products; Total Approved ENDS Reaches 45
On 5/5, FDA approved four Glas electronic nicotine delivery system products through the PMTA pathway, bringing total authorized ENDS products to 45. The decision introduces new policy inflection in tobacco regulation.
β¦ RELATED THESISCMS Launches BALANCE Model for Medicaid GLP-1 Weight Management; Coverage Begins in May
The BALANCE model provides free GLP-1 therapy paired with lifestyle support programs, expanding Medicaid access to obesity treatment.
β¦ RELATED THESISGLP-1 Users Face Greater Social Stigma Than Diet-Adherent Peers; Rice Study
A new Rice University study finds that individuals losing weight via GLP-1 face more negative social perception than those employing diet and exercise, or even individuals with untreated obesity, highlighting emerging social acceptance barriers.
WHO Guidelines Endorse GLP-1 Use for Adult Obesity Treatment
The World Health Organization's guidance published in JAMA establishes GLP-1 as standard-of-care therapy for eligible adults with obesity.
β¦ RELATED THESISDiaMedica Updates Pipeline on May 7; Preeclampsia, Stroke Programs Featured
DiaMedica Therapeutics presented Q1 results and pipeline updates for preeclampsia, fetal growth restriction, and acute ischemic stroke candidates.
Vepdegestrant Approved May 1 for ER+/HER2- Advanced Breast Cancer
The FDA approved vepdegestrant as a targeted hormone therapy option, expanding the treatment arsenal for hormone receptor-positive breast cancer.
β¦ RELATED THESISVeppanu FDA Approved; First-in-Class Protein Degrader for Breast Cancer
On May 1, FDA approved Veppanu for ER+/HER2-/ESR1-mutant advanced breast cancer. Protein degradation mechanism is key.
β¦ RELATED THESISNuvation Bio's IBTROZI sNDA Filed with FDA on May 6
Supplemental NDA for IBTROZI, for ROS1-positive advanced non-small cell lung cancer, submitted to FDA.
GLP-1 Associated with Reduced Depression, Anxiety, and Addiction Risk
Large cohort data show reduced depression, anxiety, and psychiatric hospitalization rates in semaglutide and other GLP-1 users.
β¦ RELATED THESISRice Study: GLP-1 Users Experience Greater Social Stigma Than Diet/Exercise Weight Loss
Research finds GLP-1 users report greater social stigma compared to those losing weight through diet and exercise, prompting policy discussions.
CMS BALANCE Model: Medicaid GLP-1 Coverage Begins May; Medicare Part D Follows July
Under the voluntary BALANCE model, Medicaid GLP-1 obesity treatment coverage launches May, with Medicare Part D coverage beginning July.
β¦ RELATED THESISPfizer Q1 revenue $14.45B, +5% YoY
EPS $0.75 exceeds consensus $0.72; 2026 revenue guidance $59.5-62.5B reconfirmed.
β¦ RELATED THESISVeppanu (vepdegestrant) first PROTAC FDA approval
Arvinas and Pfizer for ER+/HER2-/ESR1 mutation advanced breast cancer.
Yale-led breast cancer treatment technology receives first FDA approval
Yale-led technology receives first-ever FDA approval on May 7.
β¦ RELATED THESISVYVGART antibody-negative indication PDUFA 5/10
Decision imminent for AChR antibody-negative patients.
β¦ RELATED THESISLEQEMBI IQLIK weekly loading dose PDUFA 5/24
Eisai and Biogen Alzheimer's early treatment decision pending.
MV Hondius Hantavirus: 3 Deaths, 5 Confirmed Cases as of May 6
As of May 6, the MV Hondius hantavirus outbreak has resulted in 3 deaths and 5 confirmed cases, with co-monitoring by WHO and CDC.
Twelve Countries Implement Passenger Tracking and Observation
Canada, Germany, the Netherlands, Singapore, the United Kingdom, the United States, Switzerland, and eight other nations are actively monitoring disembarked passengers.
Five U.S. States Launch Passenger Monitoring Programs
Five U.S. states have initiated monitoring protocols for individuals who entered the country after disembarking from MV Hondius.
Global Wellness Summit Identifies Ovarian Aging Arrest as Next-Generation Biotech Keyword
The Global Wellness Summit has designated ovarian stem cell therapy and targeted ovarian fibrosis treatment as core health trends for 2026.
End of Anti-Aging Era: 'Skin Longevity' Framework Emerges
The traditional anti-aging paradigm is shifting toward 'skin longevity,' combining biotech, AI diagnostics, and novel active ingredients in integrated care regimens.
Veppanu Approved for ER+ Breast Cancer
On May 1st, the FDA approved Veppanu (bepedegertrant) for advanced and metastatic ER+/HER2- breast cancer with ESR1 mutations.
First Non-Psychiatric Dementia Agitation Treatment Approved
On April 30th, the FDA cleared the first non-psychiatric class medication for agitation associated with dementia, reducing elderly psychiatric care burden.
Idvynso HIV Treatment Approved April 21st
The doravirine and islatravir combination Idvynso gained approval as an adult HIV-1 treatment, offering a once-daily alternative to existing antiretroviral therapies.
GLP-1 Reduces Psychiatric Hospitalization and Sick Leave by 42%
A 10-year longitudinal study of approximately 100,000 patients showed semaglutide reduced psychiatric hospitalizations and sick leave by 42%, depression risk by 44%, and anxiety by 38%.
Rybelsus Oral GLP-1 Launches in U.S. Starting May 4th
Novo Nordisk began full commercial distribution of oral Rybelsus in the U.S. on May 4th, reducing injection-related barriers and expanding the GLP-1 tablet market.
FDA Approves AUVELITY for Alzheimer's Agitation on April 30
AXS-05 (bupropion/dextromethorphan) approved for Alzheimer's dementia-related agitation indication.
FDA Approves Interchangeable Insulin Glargine 'Langlara' on April 29
Lantus biosimilar approved for diabetes treatment with interchangeable designation.
FDA Advisory Panel Reviews Camizestrant and Truqap on April 30
Proceedings for ER+/HER2- early breast cancer and PTEN-deficient metastatic hormone-sensitive prostate cancer underway.
Medicare GLP-1 Bridge Program Launch Set for July 1
Monthly $50 copay guarantee for obesity medications; pilot runs July 1 through December. Millions of beneficiaries expected to benefit.
NIH Clarifies Oral GLP-1 Small-Molecule Mechanism in Reward Circuitry
Orforglipron and similar compounds modulate brain reward pathways to suppress hedonic appetite, offering non-injectable, cost-effective advantages.
FDA Proposes Excluding GLP-1 from 503B Bulk Drugs (April 30)
Semaglutide, tirzepatide, and liraglutide removed from 503B bulk drug list proposal, signaling compounding era conclusion.
Medicare GLP-1 Bridge Program Launches July 1
$50 monthly copay benefit for Foundayo, Wegovy, and Zepbound KwikPen through December 31, 2027.
Medicaid GLP-1 Coverage Reductions Expanding
California, New Hampshire, Pennsylvania, and South Carolina reductions followed by Massachusetts and Rhode Island review proceedings.
GLP-1 Indication Expansion: Atrial Fibrillation, Alcohol Disorder, Depression, Diabetic Retinopathy
April clinical data releases documented efficacy beyond obesity across four additional therapeutic domains, initiating multi-indication era.
UCSF GLP-1 Synaptic Plasticity Research
GLP-1 may influence brain neural circuit rewiring, accelerating Alzheimer's and cognitive function drug candidate pipelines.
April 2026 Β· 150
FDA Approves Langlara (Insulin Glargine-aldy) as Lantus Interchangeable Biosimilar
Sanofi's insulin glargine-aldy (Langlara) approved April 29 as interchangeable Lantus biosimilar. Expands insulin options and reduces patient burden.
Gilead's Once-Daily HIV Therapy Granted Priority Review
Bictegravir plus lenacapavir once-daily NDA received priority review April 29. Potential paradigm shift toward simplified once-daily oral HIV management.
BeOne TEVIMBRA Wins Priority Review for HER2+ Gastric/Esophageal Cancer
BeOne Medicines' TEVIMBRA granted priority review for first-line HER2+ gastroesophageal adenocarcinoma. Expands immunotherapy first-line options.
Lilly Foundayo Launches at $149 Self-Pay, $25 Insured; Competes with Novo Wegovy Tablet
Oral GLP-1 Foundayo, approved in early April, launched via LillyDirect, pharmacies, and telehealth. Pricing: $149/month lowest dose self-pay, $25 commercial insurance. Competes against Novo Nordisk Wegovy tablet (600K March prescriptions).
Novo Nordisk Wegovy Tablet Hits 600K March Prescriptions; First-Mover Advantage
Novo Nordisk Wegovy oral formulation surpassed 600K prescriptions in March, ~3 months ahead of Lilly Foundayo launch. Price and access competition intensifying.
FDA Approves Langlara Insulin Glargine Biosimilar
On April 29, the FDA approved insulin glargine-aldy (Langlara), a Lantus-compatible biosimilar for long-acting insulin treatment of diabetes.
FDA Proposes Restricting Compounding of GLP-1 Active Ingredients
On April 30, the FDA proposed limiting outsourced facility bulk compounding of semaglutide, tirzepatide, and related GLP-1 compounds, targeting illicit market channels.
Gilead's Bictegravir-Lenacapavir Once-Daily HIV Regimen Granted Priority Review
Gilead's bictegravir-lenacapavir once-daily HIV therapeutic regimen has been designated for FDA priority review, signaling simplified treatment option expansion.
Eli Lilly's Oral GLP-1 Candidate Orforglipron Advances in Approval Pathway
Eli Lilly's oral GLP-1 compound orforglipron is advancing toward regulatory approval, positioning itself as a potential advantage over Novo Nordisk's oral semaglutide (Rybelsus).
Jaguar Health's Crofelemer Demonstrates Efficacy in Cancer Drug-Induced Diarrhea Trial
On April 29, Jaguar Health announced statistically significant efficacy of Canalevia-CA1 (crofelemer) in treating chemotherapy-induced diarrhea.
FDA Approves Daraxonrasib Expanded Access in Two Days β 60% Mortality Reduction in Pancreatic Cancer
Revolution Medicines submitted 4/28; FDA approved 4/30. Based on clinical data showing 60% mortality risk reduction versus chemotherapy in previously treated metastatic PDAC.
Scancell iSCIB1+ Receives Fast Track 4/28 β Advanced Melanoma
iSCIB1+ immunotherapy granted fast-track designation for advanced melanoma treatment. Follows Opna OPN-6602 (multiple myeloma) April 15 and NextCure SIM0505 (ovarian cancer) April 7 fast tracks.
Lilly Foundayo (Orforglipron) Approved April 1 β Oral GLP-1
Once-daily GLP-1 tablet: $25 monthly with insurance; $149β349 self-pay. Medicare starts summer at $50. Direct competition with Novo Wegovy pill (600,000 prescriptions in March).
FDA Otarmeni Accelerated Approval 4/23 β OTOF Genetic Hearing Loss Gene Therapy
AAV vector-based lunsotogene parvec-cwha. Approvals same period: 4/21 Idvynso (HIV-1); 4/29 Langlara (insulin glargine biosimilar).
Tecartus (Brexu-cel) Full Approval β Relapsed/Refractory MCL
FDA converted accelerated approval to standard approval. Long-term follow-up data supports durability. ADC 'I-DXd' receives priority review for advanced SCLC.
FDA Approves Lilly's Foundayo (Orforglipron)
Eli Lilly's once-daily oral GLP-1 Foundayo received FDA approval. It is the first oral GLP-1 requiring no dietary restrictions.
ATTAIN-1 Phase 3: Up to 12-Pound Weight Loss at Highest Dose
ATTAIN-1 Phase 3 results showed 12-pound average weight loss (12.4%) at the highest dose, compared to 16.6% with oral semaglutide.
Obesity Surpasses Oncology as Top Late-Stage Therapy
For the first time in 16 years, obesity treatment leads the late-stage pipeline value hierarchy. Obesity and diabetes now comprise 38% of late-stage pipeline commercial value.
Novel Approaches Beyond GLP-1 Target Emerging
Research published April 16 suggests emerging pharmacology approaches that bypass the GLP-1 target, challenging conventional obesity treatment paradigms.
Less Than 10% of Eligible Patients Use GLP-1
GLP-1 penetration among eligible patients remains below 10%, leaving significant room for multiple market participants.
AUVELITY Alzheimer's Agitation Indication Decision Due April 30
Axsome's AUVELITY faces FDA decision on April 30 for Alzheimer's-associated agitation indication. Approval would position it as a first-line oral option.
Wegovy Oral GLP-1 Approved; First Obesity Oral Medication
The FDA approved Novo Nordisk's Wegovy oral GLP-1 for obesity indication, marking the first oral GLP-1 for weight loss. Full U.S. market entry began in January, signaling a price decline and oral medication expansion cycle in 2026.
Beyond GLP-1: GIP and Glucagon Dual-Pathway Medications Emerge
STAT reported emergence of a new drug class targeting GIP and glucagon receptors, rather than GLP-1 itself, to reduce nausea side effects. Expansion across multiple disease indications is key.
FDA Posts April 27 Notice; May 28 VRBPAC Meeting on 2026-2027 COVID Vaccines
The FDA posted a Federal Register notice on April 27 announcing a May 28 Vaccines and Related Biological Products Advisory Committee meeting to discuss 2026-2027 COVID-19 vaccine composition.
FDA Direct-to-Consumer Conference Convenes in Boston
On April 21, FDA officials, industry representatives, and academics gathered in Boston for the DTC National Conference to discuss direct-to-consumer advertising and patient access issues.
Stanford's BRP Molecule β 'Natural Ozempic' Discovered via AI
Suppresses appetite and reduces body fat without nausea or muscle loss; preclinical stage.
GLP-1 Resistance β Approximately 10% Have Genetic Non-Response
Stanford researchers clarify mechanism of Ozempic and Wegovy non-responders.
Survodutide Phase 3 β Average 16.6% Weight Loss
76-week trial shows overwhelming efficacy vs placebo (3.2%).
Down Syndrome CRISPR β Chromosome 21 Overexpression 'Silenced'
Preclinical results promising; announced April 24.
GLP-1 'Target-Switching' Hypothesis β GIP/Glucagon Pathway
Original researchers propose novel approach; potential to bypass side effects.
Eli Lilly's Orforglipron (Foundayo) Gains FDA Approval
72-week average weight loss: 12% vs. 0.9% placebo. First GLP-1 tablet without meal restrictions.
Eli Lilly Acquires Kelonia Therapeutics
Secures cancer-targeting gene therapy pipeline; deal announced April 24.
Foundayo Self-Pay Pricing Starts at $149/Month
Commercial insurance: $25/month. Medicare copay capped at $50 effective July 1.
FDA Moves to End GLP-1 Compounded Pharmacy Products
FDA negates clinical necessity; begins rulemaking to shut down compounded product sales channels.
Next-Generation GLP-1 Candidates Target Expanded Pathways
New drug candidates beyond GLP-1 targeting neurological and metabolic pathways emerging.
FDA Approves HIV-1 Treatment Idvynso on April 21
The FDA approved Idvynso (doravirine/islatravir combination) on April 21 for the treatment of adult HIV-1 infection.
Genetic Hearing Loss Gene Therapy Otarmeni Receives Accelerated Approval on April 23
Lunsotogene parvec-cwha (Otarmeni) received accelerated approval on April 23, marking the first gene therapy for inherited hearing loss.
Novo Nordisk Wegovy Oral Formulation Enters GLP-1 Pill Market
Novo Nordisk's Wegovy oral formulation gained market entry, with a starting dose of 1.5mg available at $149 monthly through pharmacies and telehealth channels.
Eli Lilly Foundayo Launches Three Months Behind Novo Nordisk
Eli Lilly's Foundayo entered the market three months after its competitor but is projected to capture 60% of the daily oral market by 2030.
Lantus Interchangeable Biosimilar Langlara Approved April 29
Insulin glargine-aldy (Langlara) received approval on April 29 as an interchangeable biosimilar to Lantus, adding pricing pressure to diabetes care.
Wegovy and Zepbound Each Lose Coverage for 12 Million
88% of remaining enrollees subject to prior authorization or BMI restrictions.
Eli Lilly Launches Foundayo (Orforglipron)
First small-molecule GLP-1 oral agent; 11% weight loss in clinical trials.
Wegovy Oral Formulation Expands Commercial Availability
Novo Nordisk begins pharmacy distribution nationwide.
Non-GLP-1 Obesity Hypothesis; GIP and Glucagon Targeting
Original researchers propose novel hypothesis: GLP-1 targeting unnecessary.
152 Million Americans Reside in Failing Air Quality Counties
Earth Day report highlights respiratory and cardiovascular risks.
GLP Diet app launches April 21; exceeds 2,500 reviews
Custom nutrition, 5-minute workouts, and progress tracking integrated for Ozempic and Mounjaro users officially launched.
Tom Brady, eMed partner to offer GLP-1 to healthcare workers at $25/month
Fixed employer cost of $25 per employee; employee copay $99 for GLP-1 solution.
GLP-1 indication broadens to atrial fibrillation, depression, diabetic retinopathy
April clinical updates hint at GLP-1 efficacy expansion to alcohol use disorder, depression, and diabetic retinopathy.
Stanford study: 10% of patients show GLP-1 resistance
One in ten patients on GLP-1 diabetes medications may experience diminished response. Next-generation targets needed.
NIH: oral small-molecule GLP-1 penetrates brain; suppresses cravings
Oral small-molecule GLP-1 drugs cross the blood-brain barrier to inhibit cravings, representing a next-generation obesity pharmacology candidate.
GLP-1 Oral Formulation Prescribed to 170K Patients in Six Weeks
The adoption curve for orals is outpacing injectables' initial trajectory, marking a paradigm shift in obesity treatment delivery.
Up to 40% of Weight Loss Attributable to Lean Muscle Depletion
Skeletal muscle loss accompanies 'Ozempic face' concerns, positioning muscle-preserving therapeutics as the next-generation priority.
FDA Approves Idvynso for Adult HIV-1 Infection on April 21
The fixed-dose combination of doravirine and islatravir expands antiretroviral options.
Otarmeni Receives Accelerated Approval for Hereditary Hearing Loss on April 23
FDA expedited lunsotogene parvec-cwha approval, broadening the gene-therapy footprint in rare diseases.
GLP-1 Drug Cycling Becomes Widespread Practice
Users frequently stop and restart medication; long-term cycling safety data remains scarce.
Eli Lilly's Foundayo Achieves Broad U.S. Distribution Post-FDA Approval (April 1)
Following April 1 FDA accelerated approval, Eli Lilly's Foundayo (orforglipron) began LillyDirect shipments April 6, then expanded to wide pharmacy and telehealth networks mid-April. It is the first oral GLP-1 formulation unrestricted by meal, water or timing.
UnitedHealth Raises 2026 Full-Year Guidance on Strong Q1 Performance
UnitedHealth posted Q1 revenue of $111.72B and adjusted EPS of $7.23, raising 2026 guidance from $17.75 to $18.25+. Medical benefit ratio of 83.9% beat consensus of 85.5%.
CMS Finalizes GLP-1 Bridge Program; Medicare 'GLP-1 Era' Begins July 1
CMS codified eligibility and Part D participation for the GLP-1 Bridge Program in April, with the demonstration running July 1, 2026βDecember 31, 2027. A temporary Medicare GLP-1 coverage bridge precedes the permanent BALANCE model launch.
FDA Generic Drug Review Times Accelerate; ANDA Approvals Faster
FDA generic drugs program monthly and quarterly activity reports released April 17 showed ANDA average approval time dropping from 35.93 months in Q1 to 32.82 months in Q2; median fell from 25.65 to 20.29 months. April saw 17 first-cycle approvals.
GLP-1 'Ozempic Personality' Side Effect Emerges Clinically; Cycling Safety Unclear
Washington Times (April 30) and NPR (April 15) reported GLP-1 patients experiencing appetite, libido and social engagement declineβtermed 'Ozempic personality'βwith some cycling drug use on and off. Long-term safety and effects of cycling remain understudied.
Lilly Foundayo (GLP-1 Pill) FDA Approval (April 1)βShipped in April
Once-daily GLP-1 pill Foundayo approved. 72-week trial highest-dose group: 12% weight loss. Medicare $50/month; insured $25 coupon; uninsured $149β349.
Idvynso (HIV Combination) Approved April 21
FDA approved Idvynso for adult HIV-1βcombining doravirine and islatravir as a novel antiretroviral regimen.
OtarmeniβGene Therapy for Hereditary Hearing Loss (Accelerated Approval, April 23)
AAV-based gene therapy Otarmeni received accelerated approval for OTOF-mediated hereditary hearing lossβlandmark for genetic hearing treatments.
Novo's Wegovy Pill Surpasses 600,000 Prescriptions in March
Wegovy oral formulation exceeded 600,000 prescriptions in March alone, outpacing initial forecasts and signaling fierce direct competition with Lilly's Foundayo.
STAT: Beyond GLP-1βNext-Generation Obesity Drug Research Accelerates (April 16)
STAT reports April 16 that developers are actively exploring non-GLP-1 targets to sidestep adverse effects and resistance. New paradigm emerging.
Eli Lilly's Foundayo gains FDA approval and hits market by April 6
Foundayo (orforglipron) received FDA approval on April 1 using the agency's new commissioner voucher program for expedited review. Insurance coverage costs $25/month; self-pay is $149. No meal restrictions required.
Novo's Wegovy pill posts record first-quarter launches; 600,000+ prescriptions
Wegovy's pill formulation set the all-time obesity-treatment launch record. Over 600,000 prescriptions were written in the first quarter. The downside: fasting and a 30-minute wait period are required.
FDA approves Regeneron's Otarmeni (AAV gene therapy for hearing loss)
Regeneron's Otarmeni gained accelerated approval on April 23 for OTOF-related hearing loss. Additional April approvals include Idvynso (HIV-1, 4/21) and Langlara, a Lantus biosimilar (4/29).
Caltech releases CellSAM for automated single-cell identification
Caltech researchers unveiled CellSAM, an AI tool for automatically identifying and segmenting individual cells across optical, fluorescence, and electron microscopy images.
Health insurance burden climbs: family premiums up 23% in five years
Workers' family insurance premiums average $6,900 after a 23% five-year increase. Two-thirds of Americans cite health-cost anxiety. Prior authorization and billing complexity add patient-safety risks.
FDA Approves Eli Lilly's Foundayo as First GLP-1 Obesity Pill
The FDA approved Eli Lilly's orforglipron (Foundayo) on April 1 as the first GLP-1 oral obesity treatment requiring no timing restrictions around food or water.
Stanford Researchers Identify 'Natural Ozempic' Molecule
Stanford researchers identified a BRP molecule that acts on appetite centers without nausea or muscle loss, dubbing it a 'natural Ozempic.' Preclinical data showed diet and body fat reductions.
New Study Flags GLP-1 Resistance in Roughly 10% of Patients
Researchers identified a genetic variant causing GLP-1 resistance in approximately 10% of patients, offering insight into disparities in drug response.
GLP-1 Users Increasingly Stop and Restart Medications Despite Medical Caution
NPR documented a rising trend of patients discontinuing and restarting GLP-1 drugs like Wegovy and Zepbound, a practice clinicians discourage but which occurs frequently in practice.
Novo Nordisk's Wegovy Captures 65% Share of New GLP-1 Prescriptions
Novo Nordisk's Wegovy commands 65% of new GLP-1 obesity drug prescriptions in the United States, extending market dominance.
Foundayo Opens GLP-1 Oral Obesity Treatment Market
Eli Lilly's Foundayo received FDA approval April 1, with cash pricing set at $149 monthly (matching oral Wegovy) and Medicare coverage starting summer at $50 monthly. Projected 2030 sales of $14.8 billion.
Utah Measles Climb to 602 Cases; U.S. Reaches 1,487
Utah has accumulated 602 measles cases with 1,487 nationally confirmed. Twenty-four new cases emerged in 2026, with 93% tied to cluster transmission. The outbreak threatens the U.S. measles elimination status.
Colorado and Pennsylvania Accelerate Avian Flu Culling
Weld County, Colorado culled 1.3 million layers; Lancaster County, Pennsylvania eliminated 720,000 layers. Over 30 days, 59 farms were affected, with 4.9 million birds culled.
FDA Proposes Excluding GLP-1 from Compounding List
The FDA proposed April 30 to exclude Novo Nordisk and Eli Lilly obesity and diabetes active pharmaceutical ingredients from the compounding allowance list, citing lack of clinical need for compounded GLP-1 products.
Late-April FDA Approvals Include HIV and Genetic Therapies
April 21: Idvynso (doravirine/islatravir) HIV-1 approval. April 23: Otarmeni accelerated approval for hereditary OTOF deafness gene therapy. April 29: Langlara (insulin glargine biosimilar) approval.
AstraZeneca Expands Tezspire Asthma Label
On April 13, the FDA granted AstraZeneca's asthma drug Tezspire (tezepelumab-ekko) expanded approval, broadening its indicated uses.
FDA Orders Eli Lilly to Submit Additional Safety Data for Foundayo
Released April 14, FDA approval documents require Eli Lilly to submit further cardiovascular and hepatic safety data on Foundayo (orforglipron). The rapid approval carried the Commissioner's National Priority Voucher.
Medicare GLP-1 Copay Cap at $50 Expands Senior Access
Medicare's GLP-1 benefits program capped out-of-pocket costs at $50 monthly, accelerating both price compression and senior adoption.
Trump Signs Psychedelic Mental Health Executive Order
The Trump administration signed an executive order in April to expedite psychedelic drug research and access for mental health, with veterans prioritized.
Neomorph's $100M Series B Funds NEO-811 Clinical Advancement
The $100 million Series B accelerates NEO-811's Phase 1/2 trials in renal cell carcinoma, setting the stage for near-term readouts.
Stanford "Natural Ozempic": AI peptide BRP
No nausea, no muscle wasting. Appetite suppression in preclinical models. Science Daily, 4/12.
GLP-1 resistance found in 10% of patients
Genome Medicine, 3/29: certain mutations blunt drug response. Precision dosing essential.
Renaissance Pharma daretabart FDA Fast Track for high-risk neuroblastoma
Anti-GD2 antibody. 4/14 announcement. Oncology momentum 4/13β15 window.
AstraZeneca Tezspire monograph updated 4/13
Tezepelumab-ekko expanded guidance. Eosinophilic asthma and general asthma standard-of-care signals shift.
Celltrion ADC CT-P71 Fast Track (4/9)
Nectin-4-targeting antibody-drug conjugate for advanced metastatic urothelial cancer. Korean ADC export accelerates.
Foundayo Oral GLP-1 FDA Approval (April 1)
FDA approved Foundayo for obese and overweight adultsβthe first oral GLP-1 receptor agonist requiring no food/water constraints before dosing.
Retatrutide -28.7% Weight Loss, -75.8% Pain
In obese adults with knee osteoarthritis, Retatrutide delivered mean -28.7% weight loss and WOMAC pain reduction of -75.8%. Regulatory submission expected in 2026.
AI Mental-Health Apps Clinically Validated
Flourish demonstrated efficacy in two large RCTs. Headspace's Ebb, Woebot, Wysa, and Ash entering mainstream clinical adoption.
AI Integration in Mental-Health Workforce: Mixed Sentiment
NPR April 7 report: mental-health professionals simultaneously embrace and fear AI adoption. Clinical safety and validation gaps persist.
Claude's Internal Emotion Vectors Identified
Mechanistic interpretability research publicly identified internal emotion vectors activating across human emotional contexts in Claude models.
AbbVie ELAHERE Plus Carboplatin: 62.7% Phase 2 ORR
At SGO 2026 (April 10β13, San Juan), AbbVie presented Phase 2 data (IMGN853-0420) showing mirvetuximab plus carboplatin achieved a 62.7% objective response rate in platinum-sensitive ovarian cancer.
Lilly's Foundayo (Oral GLP-1) Earns FDA Approval April 1
Foundayo, an oral GLP-1, received FDA approval on April 1 based on ATTAIN-1 (non-diabetic obesity/overweight) and ATTAIN-2 (diabetes plus obesity) data. Maximum-dose mean weight loss was 27.3 lbs (12.4%).
Daraxonrasib Doubles One-Year Pancreatic Cancer Survival
The RAS(ON) inhibitor daraxonrasib achieved roughly double the one-year survival rate in advanced pancreatic cancer Phase 1/2 dataβmajor oncology news dominating mid-April coverage (Northwestern, NatGeo, Dana-Farber).
FDA Grants Fast Track to Multiple Oncology Candidates in April
The FDA designated fast-track status to multiple oncology programs in April, spanning ovarian, bladder, and pancreatic indications, including PAS-004 (NF1 pathway).
FDA Launches 'Real-Time' Clinical Trials Pilot
STAT reports the FDA is piloting 'real-time clinical trials' with AstraZeneca, Amgen, and others to accelerate drug development, with oncology as the priority domain.
Foundayo oral GLP-1 starts free shipping via LillyDirect (April 6)
FDA-approved April 1; first GLP-1 pill with no meal or water restrictions. Telehealth and pharmacy rollout follows.
Boehringer Survodutide: 16.6% weight loss at 76 weeks
SYNCHRONIZE-1 Phase 3 GLP-1 plus glucagon dual agonist with waist-circumference reduction. Adverse events mild.
Celltrion CT-P71 FDA Fast Track (April 9)
Nectin-4-targeted ADC for advanced, metastatic urothelial cancer. Korean ADC global entry signal.
NextCure SIM0505 Fast Track (April 7)
Platinum-resistant ovarian cancer ADC. April early-month U.S. oncology ADC Fast Track trend firms.
Stanford: 1 in 10 carry GLP-1 genetic resistance
Specific genetic variants blunt Ozempic and Wegovy response. Precision-medicine matching becomes critical.
FDA approves Eli Lilly Foundayo (oral GLP-1)
Average 27-pound weight loss at 72 weeks, no food or water restriction needed. Approved April 1 as the first oral GLP-1 pill.
Foundayo $25 copay for insured patients
Uninsured pricing $149β$349 per dose via LillyDirect and telehealth channels.
Novo's Wegovy pill hits 600K prescriptions in March
Novo gets a three-month market head start ahead of Foundayo, cementing early share advantage.
FDA recalls Tridergel and Revitaderm antimicrobial gels April 8
Lysinibacillus fusiformis contamination prompted voluntary lot withdrawal.
Eli Lilly acquires CrossBridge Bio for $300M on April 14
Houston-based ADC oncology startup accelerates Lilly's antibody-drug conjugate portfolio expansion.
FDA Approves Lilly's Oral GLP-1 'Foundayo' April 1 Via Fast-Track
The FDA cleared Lilly's orforglipron (brand name Foundayo) through a newly established CNP voucher fast-track pathway on April 1.
Foundayo's Out-of-Pocket Low Dose Set at $149/Month
Lilly priced Foundayo's lowest dose at $149 monthly out-of-pocket, matching Novo's Wegovy tablet pricing, BioPharma Dive reported.
Wegovy Pill Crosses 600K Prescriptions Post-Launch
Novo's Wegovy tablet tallied over 600,000 prescriptions since launch, a 10-fold faster adoption rate than the legacy Wegovy injection.
Foundayo Differentiated by Meal-Time Flexibility
Lilly's Foundayo, as a small-molecule oral drug, works regardless of meal timing, unlike Wegovy's 30-minute fasting requirement.
FDA Signals End to GLP-1 Compounding Pharmacies
STAT reported April 30 that the FDA declared GLP-1 compounding "not clinically necessary," signaling a market shutdown.
FDA approves Lilly 'Foundayo' (orforglipron) April 1
Once-daily oral GLP-1 for obesity in adults. No meal or time restrictions. Peak dose: 12% weight loss.
Foundayo ships; insured patients $25/month
LillyDirect dispatch starts Monday; pharmacies and telehealth follow. Uninsured: $149β349 depending on dose.
Novo Wegovy pill hits 600K March prescriptions
Novo's pill shows early momentum: 600K+ Rx in March alone. Lilly enters ~three months late.
FDA approves 42 new drugs in Q1
April 7 release of 1Q26 tally: 42 approvals. Precision oncology, metabolic disease, HIV all active.
Idvynso (doravirine-islatravir) HIV therapy expected April 21
BioPharma Dive and FDA tracker peg late-April approval for doravirine combo. Chronic infection line expands.
FDA grants priority review to Orca-T BLA for cell immunotherapy
FDA designated Orca-T, an allogeneic stem cell and T-cell immunotherapy for acute myeloid leukemia, lymphoblastic leukemia, and MDS, for priority review.
FDA approves Dapagliflozin generics and Saxagliptin-Metformin combo April 6
Drugs.com tracker: April 6 FDA approvals included Dapagliflozin 5mg and 10mg tablets plus the Saxagliptin-Metformin combination generic.
GLP-1 one-year retention falls below 25 percent; 74 percent cite restart interest
April research shows GLP-1 one-year retention below 25 percent. Separately, 74 percent of discontinuers reported willingness to restart.
Pfizer-Valneva Lyme vaccine shows 70-plus percent efficacy in Phase 3
Pfizer and Valneva reported Phase 3 VALOR study efficacy exceeding 70 percent for their Lyme vaccine candidate in ages five and up.
Ozempic may preserve lean mass better than Mounjaro
Healthline reported semaglutide (Ozempic) shows potential advantage over tirzepatide (Mounjaro) in lean mass preservation, though part of the difference stems from tirzepatide's larger weight loss magnitude.
FDA clears Foundayo (orforglipron), April 1
FDA approved Eli Lilly's once-daily oral GLP-1 Foundayo for obesity and overweight. The ATTAIN-1 trial showed 12.4% average weight loss (27.3 pounds) at the high dose. LillyDirect began shipping April 6 at $149/month out-of-pocket.
FDA converts brexu-cel (Tecartus) to standard approval
FDA converted the CAR-T cell therapy brexu-cel (Tecartus) from accelerated to standard approval for relapsed and refractory mantle-cell lymphoma, backed by ZUMA-2 long-term follow-up.
Denali's tividenofusp alfa decision due April 5
FDA was scheduled to decide on Denali Therapeutics' tividenofusp alfa for Hunter syndrome on April 5, marking a watershed moment for rare lysosomal-storage disease.
FDA Fast Track: NextCure's SIM0505 for platinum-resistant ovarian cancer
NextCure announced FDA Fast Track designation for its ADC SIM0505 in platinum-resistant ovarian cancer on April 7. Dose optimization begins Q2 2026.
AJMC: FDA speeds approvals with single-trial pathway
AJMC reported FDA now permits one clinical trial for some new-drug approvals, speeding time-to-market but raising safety-validation concerns.
FDA clears orforglipron on April 1βfirst oral small-molecule GLP-1
Eli Lilly's orforglipron earned FDA approval April 1. Once-daily oral dosing, 0.8mg starting, with a contraindication against combining with other GLP-1s. First small-molecule GLP-1 agonist for chronic weight management.
Phase 3 ATTAIN-MAINTAIN shows sustained weight loss vs. placebo
The phase 3 ATTAIN-MAINTAIN trial demonstrated orforglipron's superiority over placebo in maintaining weight loss after semaglutide or tirzepatide injection plateaus. Most common side effects: nausea, vomiting, diarrhea, constipation, indigestion.
April PDUFA calendar flags rheumatology, neurology candidates
Rheumatology Advisor and Neurology Advisor tracked April PDUFA decisions including rheumatology and neurology novel candidates. Ongoing monitoring warranted.
Iran-conflict casualties: Bandar Mahshahr toll mounting
April 4 missile strike on Bandar Mahshahr petrochemical complex killed five and wounded 170. April 3 Karaj bridge bombing wounded 100+, straining medical systems.
Bangladesh factory fire, India road crash claim six
A gas-lighter factory fire in Dakahnya, Bangladesh on April 4 killed five. A vehicle plunge near Soza, Himachal Pradesh, India same day killed four (two children) and wounded 18.
FDA greenlights Foundayo oral GLP-1 obesity pill
April 1: FDA clears Eli Lilly's orforglipron (Foundayo) for overweight and obese adults with comorbidities. No food or water restrictions, anytime dosing. ATTAIN-1 top-dose average 12.4% weight loss (~27.3 lb).
Foundayo ships via LillyDirect April 6; rapid pharmacy rollout
Foundayo accepts prescriptions April 1, ships April 6 via LillyDirect, spreading to US retail and telehealth. Cash $149/month, commercial $25/month.
Trump's 100% drug tariff carves MFN, domestic-production escape hatch
Section 232 patent drug tariffs can hit 0% through Jan 20, 2029 under MFN pricing deals or domestic production commitments; domestic entrants get 20% (100% after four years).
Lilly buys Centessa, plants neuroscience flag with OX2R agonist
Eli Lilly scoops Centessa for $6.3B upfront plus $1.5B CVR, gaining cleminorexton OX2R agonist for narcolepsy and idiopathic hypersomnia.
Project Prometheus targets drug discovery alongside robotics, aerospace
Bezos's Physical AI lab explicitly flags drug discovery alongside aerospace and robotics. Signals industrial AI's pharma R&D crossing.
FDA clears Eli Lilly's oral GLP-1 Foundayo (orforglipron) for obesity
FDA approved Eli Lilly's oral GLP-1 drug orforglipron (Foundayo) April 1 for obesity. It's the first oral GLP-1 obesity medicine with no food or water requirements and free dosingβhead-to-head to injectables Wegovy and Zepbound. Q1's most operationally impactful approval.
Pasithea PAS-004 earns Fast Track status for NF1-associated plexiform neurofibromatosis
Pasithea Therapeutics said April 1 its next-gen macrocyclic MEK inhibitor PAS-004 earned FDA Fast Track designation for NF1-associated plexiform neurofibromatosis.
A2 Bio's A2B543 autologous CAR-T earns Fast Track for MSLN-positive solid tumors
A2 Biotherapeutics announced April 1 that A2B543, an autologous CAR-T candidate, gained FDA Fast Track for relapsed/locally advanced/metastatic MSLN-expressing solid tumors in HLA-A*02-compatible adults.
Revolution Medicines' daraxonrasib doubles survival in Phase 3 pancreatic cancer trial
Revolution Medicines reported Phase 3 data: daraxonrasib plus chemotherapy extended survival to 13.2 months versus 6.7 months for chemo aloneβa 6.5-month gain.
Foundayo positioned as Q1's most operationally significant approvalβpatient demand, payer, pharmacy impact
Lumistry flagged Foundayo as Q1's most operationally impactful approval, citing patient demand, payer coverage shifts, and pharmacy dispensing potential.
FDA approves Eli Lilly oral GLP-1 'Foundayo' for obesity April 1
FDA cleared orforglipron (Foundayo) on April 1, shipping via LillyDirect starting April 6. Lowest-dose patient cash price: $149 monthly, matching Novo Nordisk's Wegovy.
FDA approves Awiqli, first once-weekly basal insulin
Drugs.com records FDA clearance of insulin icodec (Awiqli) on March 26 as the first once-weekly basal insulin for type 2 diabetes in adults.
FDA accelerates Kresladi for pediatric LAD-I
FDA granted accelerated approval to Kresladi on March 27 for pediatric severe leukocyte adhesion deficiency (LAD-I).
Eli Lilly acquires Centessa for roughly $6.3 billion
Dealroom reports Eli Lilly announced March 31 acquisition of Centessa Pharmaceuticals for approximately $6.3 billion, bolstering post-GLP-1 pipeline.
FDA accelerates Avlayah for Hunter Syndrome
Drugs.com notes FDA accelerated approval of tividenofusp alfa-eknm (Avlayah) on March 25 for Hunter Syndrome (MPS II).